Abstract 896P
Background
This study aimed to explore the efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinomas (LA-HNSCCs).
Methods
In this prospective, single-arm, single-centre clinical trial, patients meeting the inclusion criteria were treated neoadjuvant therapy of preoperatively with 200 mg pembrolizumab combined with 75 mg/m2 cisplatin and 175 mg/m2 paclitaxel. This was followed by surgery and postoperative adjuvant therapy. The primary endpoint was the postoperative pathological complete response (PCR) rate. All statistical analyses were performed using SPSS 26.
Results
A total of 22 patients were enrolled, and the baseline characteristics were shown in Fig. 1. The postoperative PCR rate, was 36.4% (8/22), and there was no delay to surgery due to adverse drug reactions. The rate of laryngeal function preservation was 90.9% (20/22). Delayed wound healing was the main surgical complication, with an incidence of 22.7% (5/22). The median follow-up time was 9.5 months, and only 1 patient (4.55%) suffered a regional recurrence.
Table: 896P
Variables | Number of patients | % |
Male/Female | 21/1 | |
Age (mean ± SD, years) | 58.1±10.49 (22∼69) | -- |
Primary site | ||
Oropharynx | 6 | 27.3 |
hypopharynx | 15 | 68.2 |
Oral Cavity | 1 | 4.5 |
Hypopharynx invasion (N=15) | ||
Fixed vocal cord | 9 | 60 |
Extend to esophagus | 2 | 13.3 |
Tobacco | ||
YES | 16 | 72.7 |
NO | 6 | 27.3 |
Alcohol | ||
YES | 15 | 68.2 |
NO | 7 | 31.8 |
P16 states | ||
Positive | 4 | 18.2 |
Negative | 18 | 81.8 |
T stage | ||
T1-T2 | 8 | 36.4 |
T3 | 7 | 31.8 |
T4 | 7 | 31.8 |
N stage | ||
N0-N1 | 3 | 13.6 |
N2 | 19 | 86.4 |
Stage | ||
II | 3 | 13.6 |
III | 3 | 13.6 |
IV | 16 | 72.7 |
PD-L1 combined positive score | ||
<5 | 7 | 31.8 |
5-10 | 2 | 9.1 |
≥10 | 13 | 59.1 |
Conclusions
Preoperative treatment with pembrolizumab and chemotherapy in resectable LA-HNSCC has a high PCR rate with no significant impact on surgical safety. This treatment was found to increase the rate of laryngeal function preservation. However, the effects of neoadjuvant immunotherapy on long-term prognosis in LA-HNSCCs require further study.
Clinical trial identification
Trial registration: Chinese Clinical Trial Registry, ChiCTR2200055719, Registered 16 January 2022.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Beijing Hope Run Special Fund of Cancer Foundation of China (Grant No.LC2021A16).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
942P - Response to salvage chemotherapy with paclitaxel +/- cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster session 12
944TiP - Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial
Presenter: Bálint Tamaskovics
Session: Poster session 12
1089P - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Presenter: Paolo Ascierto
Session: Poster session 12
1090P - Outcome impact of time from complete resection to start of adjuvant immunotherapy in stage III-IV melanoma patients
Presenter: Sergio Martinez Recio
Session: Poster session 12
1092P - Adjuvant treatment with anti-PD-1 in acral melanoma patients: A nationwide study
Presenter: Manja Bloem
Session: Poster session 12
1093P - Neoadjuvant (NeoAd) intratumoral (IT) TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab (NIVO) for patients (pts) with operable locoregionally advanced melanoma
Presenter: Ahmad Tarhini
Session: Poster session 12
1094P - Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
Presenter: Elizabeth Burton
Session: Poster session 12
1095P - Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Presenter: Irene Reijers
Session: Poster session 12